Teza Capital Management LLC Trims Position in IQVIA Holdings Inc. (NYSE:IQV)

Teza Capital Management LLC trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,691 shares of the medical research company’s stock after selling 240 shares during the period. Teza Capital Management LLC’s holdings in IQVIA were worth $922,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock valued at $841,461,000 after acquiring an additional 712,958 shares in the last quarter. Geode Capital Management LLC grew its stake in IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after acquiring an additional 77,981 shares in the last quarter. Invesco Ltd. grew its stake in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after acquiring an additional 902,226 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock valued at $481,380,000 after acquiring an additional 59,426 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent research reports. Citigroup dropped their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Stifel Nicolaus dropped their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Robert W. Baird dropped their price objective on shares of IQVIA from $195.00 to $161.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Finally, Hsbc Global Res cut shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $230.76.

IQVIA Trading Up 1.6%

Shares of IQV opened at $142.66 on Monday. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The company has a 50-day moving average of $159.83 and a 200 day moving average of $185.72. The firm has a market capitalization of $24.68 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. During the same quarter last year, the business posted $2.54 EPS. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.